{"entity":{"id":"laurence-albiges","kind":"person","name":"Laurence Albiges","aka":[],"tldr":"French kidney cancer specialist who co-led CheckMate 214 and the belzutifan trials.","summary":"Laurence Albiges was a lead investigator of CheckMate 214 (nivolumab plus ipilimumab) and of the LITESPARK trials that established belzutifan, the first HIF-2 alpha inhibitor, for previously treated clear-cell renal cell carcinoma. She led the CheckMate 214 long-term follow-up analyses and chairs the ESMO renal cancer guideline group. She heads medical oncology at Gustave Roussy.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Albiges%20L%5BAuthor%5D%20renal%20cell"}],"tags":["rcc","hif2a","guidelines"],"related":[],"cancers":["rcc"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":["hif2a","pd1"],"drugs":["belzutifan","nivolumab","ipilimumab"],"companies":[],"institutions":["gustave-roussy"],"pathways":[],"terms":[],"trials":["checkmate-214","litespark-005"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["esmo-open"],"dependsOn":[],"notes":[],"role":"Head of the Department of Medical Oncology, Gustave Roussy","institutionId":"gustave-roussy","specialisms":["Renal cell carcinoma","Immunotherapy","HIF-2 alpha inhibition","Treatment sequencing"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Albiges%20L%5BAuthor%5D%20renal%20cell"}],"papers":[{"title":"Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial","journal":"ESMO Open","year":2020,"doi":"10.1016/j.esmoop.2020.001079"},{"title":"Belzutifan versus everolimus for advanced renal-cell carcinoma (LITESPARK-005)","journal":"NEJM","year":2024,"doi":"10.1056/NEJMoa2313906"}]},"route":"/people/laurence-albiges/","neighbours":{"cancer":[{"id":"rcc","kind":"cancer","name":"Renal cell carcinoma","route":"/cancers/rcc/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"target":[{"id":"hif2a","kind":"target","name":"HIF-2α","route":"/targets/hif2a/"},{"id":"pd1","kind":"target","name":"PD-1","route":"/targets/pd1/"}],"drug":[{"id":"belzutifan","kind":"drug","name":"Belzutifan","route":"/drugs/belzutifan/"},{"id":"ipilimumab","kind":"drug","name":"Ipilimumab","route":"/drugs/ipilimumab/"},{"id":"nivolumab","kind":"drug","name":"Nivolumab","route":"/drugs/nivolumab/"}],"institution":[{"id":"gustave-roussy","kind":"institution","name":"Gustave Roussy","route":"/institutions/gustave-roussy/"}],"trial":[{"id":"checkmate-214","kind":"trial","name":"CheckMate 214","route":"/trials/checkmate-214/"},{"id":"litespark-005","kind":"trial","name":"LITESPARK-005","route":"/trials/litespark-005/"}],"journal":[{"id":"esmo-open","kind":"journal","name":"ESMO Open","route":"/journals/esmo-open/"}]}}